Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Afraxis, Servier to collaborate on CNS disease treatments
June 2013
SHARING OPTIONS:

SAN DIEGO—April closed on the announcement that Afraxis Inc. and Institut de Recherches Servier launched a non-exclusive platform collaboration using Afraxis' Enhanced Spine Platform (ESP) Technology to discover drugs to treat central nervous system disorders. Financial terms were not disclosed. The ESP technology can adapt to many central nervous system disease models and enables characterization of disease profiles, assessment of preclinical drug efficacy, identification of optimal dosing regimens or identification of undesirable side effects.
 
"Servier has a strong commitment to CNS therapeutics, and their interest in the ESP technology further illustrates the potential of this platform in a drug discovery setting," Carmine Stengone, president and CEO of Afraxis, said in a statement. "We are excited to kick-off this collaboration with Servier and look forward to a fruitful relationship."

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.